A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

Neoplasms Clinical Trial

Official title:

A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01555242
• Other study ID #: OMN54-101
• Status: Completed
• Phase: Phase 1
• First received: March 13, 2012
• Last updated: April 7, 2015
• Start date: August 2012
• Est. completion date: January 2014

Study information

• Verified date: April 2015
• Source: Omnitura Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.

Description:

Patients who complete a 28-day cycle, may be eligible to continue receiving Aneustat™ (OMN54) in 4-week increments for up to 6 cycles (inclusive of cycle 1) if further treatment is judged to be of possible benefit; if patient has not experienced unacceptable toxicity; and no study withdrawal criteria has been met.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: January 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological or cytological evidence of malignancy

• Male or female, 18 years or older

• Presence of advanced tumours, i.e., measurable or non-measurable disease (RECIST criteria, version 1.1)that have recurred or progressed following standard therapy

• Able to swallow the oral capsule form of the drug

• Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.

• Haematology within 7 days of Day 1 (initial dose):

• Hemoglobin (Hb) > 9.0 g/dL

• Platelets = 100,000 cells/mm3 (or, =100 x 10/L)

• Absolute neutrophil count (ANC) > 1.5 cells x109/L (or, > 1500 cells/mm3)

• Chemistry within 7 days of Day 1 (initial dose):

• AST(SGOT)/ALT(SGPT) = 2.5 x ULN if no liver metastases, AST(SGOT)/ALT(SGPT) < 5 x ULN if liver metastases

• Bilirubin < 1.5 x ULN unless Gilbert's Syndrome

• Serum creatinine = 1.25 ULN

• Coagulation within 7 days of Day 1 (initial dose):

*INR = 1.5

• ECOG Performance Status between 0 - 2 and estimated life expectancy of > 3 months.

• Having the initiative and means to be compliant with the protocol (as judged by the Principal Investigator) and is within a feasible geographical proximity of the study center to make the required study visits.

• Written informed consent obtained prior to any study screening procedures

• Females of childbearing potential (a female is considered of childbearing potential unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or is without a uterus) must have a negative urine pregnancy test (UPT) within 7 days of Day 1 (initial dose)

• Females of childbearing potential must agree to use an effective method of contraception (i.e., sexual abstinence, condoms, intrauterine device, diaphragm) from Screening period and throughout study participation.

Exclusion Criteria:

• Patient has uncontrolled or symptomatic brain metastases (If a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days prior to Day 1 dosing).

• Use of an investigational medication or device within 30 days of initiating study therapy (Day 1).

• Major surgery within 30 days prior to first dose (Day 1).

• Radiotherapy, chemotherapy, or immunotherapy within 28 days prior to Day 1 (not including palliative radiotherapy at focal sites).

• Pregnancy or lactation.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NY Heart Association Class III or IV, see Appendix 3), unstable angina pectoris, unstable cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.

• Screening (within approximately 28 days of registration) 12-lead electrocardiogram (ECG) that is abnormal and clinically significant

• Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.

• Use of warfarin, i.e., Coumadin®, Jantoven® within 7 days prior to Day 1 (initial dosing)

• Intolerance or aversion to porcine ingredients that are used for the OMN54 oral capsules in the investigational medicine, OMN54 (Aneustat™).

• Known hypersensitivity to any of the three botanical constituents of Aneustat™ (OMN54), or other similar plants; or to plants belonging to Labiatae or Lamiaceae families, soy, or Aneustat™ (OMN54) excipients

• Use of Sophora subprostrata root (SSR) or herba serissae within 14 days prior to Day 1.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Aneustat (OMN54)
100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID

Locations

Country	Name	City	State
Canada	BC Cancer Agency-Vancouver Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Omnitura Therapeutics, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) of two dosing regimens (once daily and twice daily)	The maximum tolerated dose (MTD) is defined as the dose, based on data from 6 patients (or 5 patients if one patient has withdrawn due to non-Aneustat (OMN54) related reasons), below the non-tolerated dose (DL T).		Yes
Primary	Dose Limiting Toxicity (DLT) of two dosing regimens (once daily and twice daily)	Assessment per Common Terminology Criteria for Adverse Events (CTCAE) v4.03.		Yes
Primary	Plasma blood concentrations of chemical markers	These measurements are intended to characterize the pharmacokinetics of Aneustat (OMN54)		No
Secondary	Tumor Response	Tumor response as per RECIST criteria version 1.1, and tumor markers in plasma, as applicable		No
Secondary	Measurement of pathway biomarkers in plasma	Plasma concentrations of cancer-related proteins to help characterize Aneustat (OMN54) activity		No